pipette
ESEspañol

Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

Shun Lu, Nicolas Girard, James Chih-Hsin Yang, Frances A. Shepherd, Xiaorong Dong, Surein Arulananda, Giulio Metro, Hidetoshi Hayashi, Laura Bonanno, Yu Jung Kim, Zhe Liu, Myung-Ju Ahn, Yuping Sun, Thuong Vu Le, Silvia Novello, Sang-We Kim, Yanqiu Zhao, Toàn Nguyễn Khánh, Mariana Brandão, Yongsheng Wang, Missak Haigentz, Daniel Misch, Mariano Provencio Pulla, Wen-Tsung Huang, Clarissa Serodio da Rocha Baldotto, Marcelo Daniel Tatangelo, Colin R. Lindsay, Ryan James Hartmaier, Rafal Lolo, Balakumar Swaminathan, Alexander Gont, Francis María Esposito, Yusuke Okuma

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Osimertinib–savolitinib led to significantly longer progression-free survival than platinum–pemetrexed (hazard ratio for disease progression or death, 0.55; 95% confidence interval [CI], 0.42 to 0.72; P<0.001), as well as significantly longer overall survival (hazard ratio for death, 0.68; 95% CI, 0.50 to 0.91; P=0.01; final analysis).

Appeared: Tuesday, October 27. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2611335